Navigation Links
Dabur India Q4 Profit Surges 31%

The Board of Directors of Dabur India Ltd (DIL) met here today to consider the audited financial results of the company for the quarter and the full year ending March 31, 2007.

Dabur India Limited is one of Indias leading FMCG Companies. Building on a legacy of quality and experience for over 120 years, Dabur today is Indias most trusted name and the worlds largest Ayurvedic and Natural Health Care Company. The largest Indian Personal Care and Health Care Company, Dabur India is also a world leader in Ayurveda with a portfolio of over 250 Herbal/Ayurvedic products.

Riding on strong growth across its core categories, Dabur India Ltd recorded a 30.8 per cent increase in net profit during the fourth quarter of 2006-07 to Rs 65.70 crore as against Rs 50.22 crore in the corresponding quarter of the previous fiscal. Its turnover for the quarter stood at Rs 444.76 crore, up 33.7 per cent over Rs 332.69 crore earned a year earlier.

For the full year ended March 31, 2007, Dabur India net profit surged by 33.3 per cent to Rs 252.08 crore from Rs 189.08 crore in 2005-06. Its turnover for the fiscal also marked a 29.8 per cent growth at Rs 1778.02 crore from Rs 1369.68 crore a year earlier.

Dabur India has recorded strong growth in key categories like hair and oral care, health supplements, foods and home care. The Foods Business recorded a strong growth of 28 per cent during the year, while the international business posted a growth of 29.3 per cent, driven by our business in Egypt, Pakistan and the GCC region, Dabur India Ltd Chief Executive Officer Mr. Sunil Duggal said

In the Oral Care category, toothpaste sales led by Babool and Dabur Red reported a 28 per cent growth year-on-year. Vatika led the growth in the Shampoo category, which posted a 31 per cent surge in sales during the year. With this, Dabur has emerged as the fastest growing player in the highly competitive Shampoo and Oral Care categories .

The Health Supplements category continued its strong performance ending the year with a growth of 19.5 per cent. Dabur India's Home Care portfolio sales also surged 35.1 per cent, with Odonil growing by 28.2 per cent and Odomos by 71 per cent.

The Board of Directors has recommended that the interim dividend announced earlier be considered as the final dividend for the year. We have maintained out pay-out policy in 2006-07 and have disbursed a total dividend of 213% during the year on pre-bonus capital, Dabur India chairman Mr. V C Burman said.

Dabur India (Consolidated)

Dabur India Ltd (Consolidated) recorded a 53.9 per cent surge in net profit during the fourth quarter of the 2006-07 financial year. Its net profit for the quarter stood at Rs 76.91 crore, up from Rs 49.96 crore in the same period last year. Turnover for the quarter also marked a 20.1 per cent increase to Rs 576.49 crore from Rs 479.93 crore in the corresponding quarter of the previous fiscal.

For the financial year ended March 31, 2007, consolidated net profit soared 32.2 per cent to Rs 283.04 crore as against Rs 214.18 crore in the previous fiscal. Consolidated turnover for the full year stood at Rs 2233.72 crore, a jump of 17.6 per cent over Rs 1899.57 in 2005-06.

Overseas sales also recorded significant gains, growing by 29.3 per cent in 2006-07 with strong performances across most focus markets. We have built strong capabilities to tap emerging opportunities. Sales in the GCC region have increased by 29 per cent, while Dabur Egypt reported a 59 per cent growth. Sales in Pakistan touched Rs 20 crore, and exports to new markets in the Middle East and North Africa have commenced, said Dabur India Ltd Group Director Mr. P D Narang.


'"/>




Related medicine news :

1. Dabur Research to set up Drug Discovery Center in Oman
2. Is Diabetes the Leading Cause of Kidney Failure in India
3. AIDS Disaster in India is Imminent
4. Indian Prime Minister has successful Knee Replacement Surgery
5. International community warns India on HIV situation
6. India takes on foot-and-mouth disease by vaccinating animals
7. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
8. India to benefit from pharma companies move
9. Healthcare sector is now a multi billion-dollar industry in India
10. The World Bank funds private Hospital in India
11. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... ... 20, 2017 , ... ATP Science, an Australian-based company focused ... the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding meetings ... of supplements that keep the body functioning at its peak performance by providing ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior ... MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
Breaking Medicine Technology: